ACM
RGNX icon

Asymmetry Capital Management’s Regenxbio RGNX Stock Holding History

Asymmetry Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,692
Closed -$1.2M – 42
2018
Q2 		$1.2M Buy
16,692
+684
+4% +$32.7K 1.18% 28
2018
Q1 		$478K Buy
+16,008
New +$466K 0.6% 34
2017
Q4 		– Sell
-13,448
Closed -$443K – 37
2017
Q3 		$443K Sell
13,448
-458
-3% -$10.3K 0.51% 31
2017
Q2 		$275K Buy
13,906
+1,508
+12% +$29.2K 0.33% 27
2017
Q1 		$239K Buy
+12,398
New +$239K 0.33% 26

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Asymmetry Capital Management's RGNX Position: Q3 2018 in Review

Asymmetry Capital Management sold out of Regenxbio (RGNX) in Q3 2018, closing a stake of 16,692 shares — an estimated $1.2M sold.

Asymmetry Capital Management first reported a position in RGNX in Q1 2017 and held it in 5 quarters. The position peaked at $1.2M in Q2 2018. 203 funds tracked by Wall St. Rank hold RGNX as of Q3 2018.

  • Asymmetry Capital Management reported no remaining Regenxbio position as of Q3 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 16,692 Regenxbio shares in Q3 2018, an estimated $1.2M.
  • Asymmetry Capital Management first reported a position in Regenxbio in Q1 2017 and held it in 5 quarters.
  • Asymmetry Capital Management's Regenxbio position peaked at $1.2M in Q2 2018.
  • 203 funds tracked by Wall St. Rank held Regenxbio as of Q3 2018.

Based on Asymmetry Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.